Trial reportDiabetes, obesity & metabolism2025
A 7-year prospective analysis of sustained benefits of multicomponent risk assessment and data-driven care in patients with type 2 diabetes: The Malaysian JADE Program.
Trial report in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A 7-year prospective analysis of sustained benefits of multicomponent risk assessment and data-driven care in patients with type 2 diabetes: The Malaysian JADE Program.Diabetes, obesity & metabolism · 2025Trial
- Nurses' Roles in Supporting Digital Engagement and Self-Management in Adults with Type 2 Diabetes: A Scoping Review.Nursing reports (Pavia, Italy) · 2026Review
- Redefining Diabetes and Creating Solutions-The Hong Kong Diabetes Register: Kelly West Award Lecture 2025.Diabetes care · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
aimWe evaluated the sustained effects of multicomponent risk assessment and data-driven care augmented by the web-based Joint Asia Diabetes Evaluation (JADE) Platform with a built-in template to guide comprehensive assessment (CA) for risk stratification on top of usual care in patients with type 2 diabetes (T2D) from Malaysia.
methodsIn 2012-2015, 1196 T2D patients participated in a 1-year JADE Program randomised to (1) CA-only, (2) receipt of a JADE personalised report (CA + R) to empower self-care, or (3) engagement by nurse phone calls (CA + R + T). In 2020-2022, patients underwent repeat CA for evaluation of attainment of ≥2 ABC targets (HbA1c <7%, Blood pressure <130/80 mmHg, low-density lipoprotein Cholesterol [LDL-C] <2.6 mmol/L) and diabetes-related endpoints.
resultsAfter 7.5 ± 0.5 (mean ± SD) years, 138 (11.5%) patients had died, 232 (19.4%) defaulted, and 826 (69.1%) patients returned. The deceased had more complications, while non-returnees were younger, with fewer complications but worse risk factor control than returnees at baseline. Using inverse probability weighting and logistic regression, attaining ≥2 ABC targets was associated with CA + R + T (vs. CA-only) with an odds ratio (OR, 95% confidence interval) of 1.57 (1.02-2.41, p = 0.041). Other predictors included age [1.05 (1.04-1.07, p < 0.001)], diabetes duration [0.97 (0.95-0.99, p = 0.003)], JADE risk category 3 [0.41 (0.26-0.66), p < 0.001] and risk category 4 (vs. category 1 and 2) [0.22 (0.12-0.38), p < 0.001]. Amongst participants without complications at baseline, CA + R + T was associated with an incidence rate ratio of 0.89 (0.78-1.00, p = 0.043) for any diabetes-related endpoints.
conclusionsTechnology-assisted multicomponent risk assessment and data-driven care for 1-year identified high-risk patients and improved outcomes after 7 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.